

West London Mental Health NHS Trust Performance in Initiating Q4 17/18

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
17/SS/0013	202663	XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects with Mild Dementia due to Alzheimer's Disease (AD)	Yes	12/12/2017	14	161	175	No	15/03/2017	20/06/2017	25/04/2017	21/06/2017	04/07/2017	Please Select...	05/06/2017	G - No patients consented	Eligible patients seen but no consent	Neither
17/LO/0380	218003	CREAD 2 - A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of crenezumab in patients with prodromal to mild Alzheimer's disease	No					Site Not Confirmed	05/12/2016	03/05/2017	18/05/2017			Site declined to participate				Please Select...
16/NE/0399	215044	A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Dementia with Lewy Bodies (DLB)	Yes	15/06/2017	12	36	48	Yes	17/02/2017	28/04/2017	16/02/2017	05/05/2017	10/05/2017	Please Select...	05/05/2017			Please Select...
17/WM/0146	220303	A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month	No		132			No	01/05/2017	21/09/2017	04/10/2016	23/01/2018	31/01/2018	Please Select...	12/02/2018	E - Staff availability issues	Waiting for new PI to be appointed	NHS Provider

		Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease.																
16/LO/1622	189449	Investigation of a New Satiety Inducing Diet for the Treatment of Obesity in the NHS	Yes	29/11/2017	6	119	125	No	24/04/2017	27/07/2017	26/09/2016	02/08/2017	02/08/2017	Please Select...	02/08/2017	J - Other	Issue of room availability for the clinics from which the study was recruiting.	NHS Provider
17/EE/0114	221275	A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)	Yes	01/01/2018	34	-9	25	Yes	07/12/2017	07/12/2017	12/06/2017	09/01/2018	10/01/2018	Please Select...	10/01/2018	D - Sponsor Delays H - Contracting delays	The first participant was recruited prior to site selection due to study design (feeder study) and contract delays.	Sponsor
16/SS/0115	206867	A Parallel-Group, Double-Blind, Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD).	Yes	11/12/2017	20	26	46	Yes	20/10/2017	26/10/2017	25/08/2016	10/11/2017	15/11/2017	Please Select...	15/11/2017			Please Select...
17/SC/0081	221195	A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with	Yes	16/11/2017	0	22	22	Yes	23/10/2017	25/10/2017	21/04/2017	25/10/2017	25/10/2017	Please Select...	25/10/2017			Please Select...

		Alzheimer's Disease															
16/NE/0023/AM07	190035	A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of crenezumab in patients with Prodromal-to-mild Alzheimer's disease (BN29553)	No					Site Not Confirmed	08/06/2017	08/06/2017				Site declined to participate			Please Select...

West London Mental Health NHS Trust Performance in Delivery Q4 17/18

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
27691	14/LO/1994	161812	A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)	Number Agreed	15	15	Date Agreed	01/10/2016	5	30/05/2017	9	Recruitment Finished	
27692	16/NE/0191	202345	A Phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB)	Number Agreed	1	7	Date Agreed	31/12/2016	0	14/04/2017	3	Withdrawn By Sponsor	
27693	16/WS/0138	208282	A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (ACADIA)	Number Agreed	5	5	Date Agreed	02/04/2018	2	04/10/2017	2	Withdrawn By Sponsor	
27694	17/SC/0081	221195	"A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer's Disease"	Number Agreed	2	2	Date Agreed	01/02/2020	2	28/11/2017	2	Withdrawn By Sponsor	The Sponsor decided to stop recruitment early, because there was a potential overlap with another study of theirs.